Mechanisms underlying allergy vaccination with recombinant hypoallergenic allergen derivatives

Vaccine

Volumn 30, Issue 29, 2012, Pages 4328-4335

  Linhart, Birgit ^a   Valenta, Rudolf ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Allergen; Allergy; Allergy vaccination; Allergy vaccines; Hypoallergens

Indexed keywords

ALUMINUM HYDROXIDE; BIRCH POLLEN ALLERGEN BET V 1; CD23 ANTIGEN; FISH ALLERGEN CYP C 1; GRASS POLLEN ALLERGEN PHL P 5; GRASS POLLEN ALLERGEN PHL P 6; HOUSE DUST ALLERGEN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G ANTIBODY; PLACEBO; POLLEN ANTIGEN; RECOMBINANT ALLERGEN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ALLERGENICITY; ALLERGY; B LYMPHOCYTE; BIRCH; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); CRYSTALLIZATION; DELAYED HYPERSENSITIVITY; DOUBLE BLIND PROCEDURE; DRUG SCREENING; ESCHERICHIA COLI; FISH DISEASE; FOOD ALLERGY; GEL PERMEATION CHROMATOGRAPHY; GRASS POLLEN; HISTAMINE RELEASE; HOUSE DUST ALLERGY; HUMAN; IMMUNIZATION; IMMUNOBLOTTING; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; MASS SPECTROMETRY; NONHUMAN; OLIGOMERIZATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 3 CLINICAL TRIAL (TOPIC); POLLEN ALLERGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCIENTIST; SITE DIRECTED MUTAGENESIS; SKIN MANIFESTATION; SKIN TEST; SUBCUTANEOUS IMMUNOTHERAPY; T LYMPHOCYTE; VACCINATION; WILD TYPE;

ALLERGENS; ANIMALS; CLINICAL TRIALS AS TOPIC; DESENSITIZATION, IMMUNOLOGIC; HUMANS; HYPERSENSITIVITY; IMMUNOGLOBULIN E; VACCINATION; VACCINES;

EID: 84861963114     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.11.011     Document Type: Review

References (115)

1. Floistrup H., Swartz J., Bergstrom A., Alm J.S., Scheynius A., van Hage M., et al. Allergic disease and sensitization in Steiner school children. J Allergy Clin Immunol 2006, 117:59-66. The Parsifal Study.
2. Kay A.B. Allergy and allergic diseases 2008, Blackwell Science, Oxford.
3. Noon L. Prophylactic inoculation against hay fever. Lancet 1911, 1:1572-1573.
4. Cooke R.A., Barnard J.H., Hebald S., Stull A. Serological evidence of immunity with coexisting sensitization in a type of human allergy. J Exp Med 1935, 62:733-750.
5. Bousquet J., Lockey R., Malling H.J. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 1998, 102:558-562.
6. Durham S.R., Walker S.M., Varga E.M., Jacobson M.R., O'Brien F., Noble W., et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999, 341:468-475.
7. Möller C., Dreborg S., Ferdousi H.A., Halken S., Høst A., Jacobsen L., et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002, 109:251-256.
8. Focke M., Marth K., Flicker S., Valenta R. Heterogeneity of commercial timothy grass pollen extracts. Clin Exp Allergy 2008, 38:1400-1408.
9. Focke M., Marth K., Valenta R. Molecular composition and biological activity of commercial birch pollen allergen extracts. Eur J Clin Invest 2009, 39:429-436.
10. Curin M., Reininger R., Swoboda I., Focke M., Valenta R., Spitzauer S. Skin prick test extracts for dog allergy diagnosis show considerable variations regarding the content of major and minor dog allergens. Int Arch Allergy Immunol 2011, 154:258-263.
11. Trivedi B., Valerio C., Slater J.E. Endotoxin content of standardized allergen vaccines. J Allergy Clin Immunol 2003, 111:777-783.
12. van der Veen M.J., Mulder M., Witteman A.M., van Ree R., Aalberse R.C., Jansen H.M., et al. False-positive skin prick test responses to commercially available dog dander extracts caused by contamination with house dust mite (Dermatophagoides pteronyssinus) allergens. J Allergy Clin Immunol 1996, 98:1028-1034.
13. Valenta R. The future of antigen-specific immunotherapy of allergy. Nat Rev Immunol 2002, 2:446-453.
14. Niederberger V., Pauli G., Grönlund H., Fröschl R., Rumpold H., Kraft D., et al. Recombinant birch pollen allergens (rBet v 1 and rBet v 2) contain most of the IgE epitopes present in birch, alder, hornbeam, hazel, and oak pollen: a quantitative IgE inhibition study with sera from different populations. J Allergy Clin Immunol 1998, 102:579-591.
15. Niederberger V., Laffer S., Fröschl R., Kraft D., Rumpold H., Kapiotis S., et al. IgE antibodies to recombinant pollen allergens (Phl p 1, Phl p 2, Phl p 5, and Bet v 2) account for a high percentage of grass pollen-specific IgE. J Allergy Clin Immunol 1998, 101:258-264.
16. Jutel M., Jaeger L., Suck R., Meyer H., Fiebig H., Cromwell O. Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol 2005, 116:608-613.
17. Pauli G., Larsen T.H., Rak S., Horak F., Pastorello E., Valenta R., et al. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. J Allergy Clin Immunol 2008, 122:951-960.
18. Larenas-Linnemann D. Oralair Birch, a recombinant major birch pollen allergen tablet for sublingual immunotherapy of allergic rhinitis caused by birch pollen. Curr Opin Investig Drugs 2010, 11:586-596.
19. Mellerup M.T., Hahn G.W., Poulsen L.K., Malling H. Safety of allergen-specific immunotherapy. Relation between dosage regimen, allergen extract, disease and systemic side-effects during induction treatment. Clin Exp Allergy 2000, 30:1423-1429.
20. Stull A., Cooke R.A., Sherman W.B. Experimental and clinical studies of fresh and modified pollen extracts. J Allergy 1940, 11:439.
21. Marsh D.G., Lichtenstein L.M., Campbell D.H. Studies on allergoids prepared from naturally occurring allergens. I. Assay of allergenicity and antigenicity of formalinized rye group I component. Immunology 1970, 18:705-722.
22. Niederberger V., Horak F., Vrtala S., Spitzauer S., Krauth M.T., Valent P., et al. Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci USA 2004, 101(Suppl. 2):14677-14682.
23. Valenta R., Ferreira F., Focke-Tejkl M., Linhart B., Niederberger V., Swoboda I., et al. From allergen genes to allergy vaccines. Annu Rev Immunol 2010, 28:211-241.
24. Linhart B., Valenta R. Molecular design of allergy vaccines. Curr Opin Immunol 2005, 17:646-655.
25. Norman P.S., Ohman J.L., Long A.A., Creticos P.S., Gefter M.A., Shaked Z., et al. Treatment of cat allergy with T-cell reactive peptides. Am J Respir Crit Care Med 1996, 154:1623-1628.
26. O'Hehir R.E., Busch R., Rothbard J.B., Lamb J.R. An in vitro model of peptide-mediated immunomodulation of the human T cell response to Dermatophagoides spp (house dust mite). J Allergy Clin Immunol 1991, 87:1120-1127.
27. Haselden B.M., Kay A.B., Larché M. Immunoglobulin E-independent major histocompatibility complex-restricted T cell peptide epitope-induced late asthmatic reactions. J Exp Med 1999, 189:1885-1894.
28. Vrtala S., Hirtenlehner K., Vangelista L., Pastore A., Eichler H.G., Sperr W.R., et al. Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments: candidates for a novel form of specific immunotherapy. J Clin Invest 1997, 99:1673-1681.
29. Vrtala S., Hirtenlehner K., Susani M., Akdis M., Kussebi F., Akdis C.A., et al. Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen Bet v 1. FASEB J 2001, 15:2045-2047.
30. Vrtala S., Akdis C.A., Budak F., Akdis M., Blaser K., Kraft D., et al. T cell epitope-containing hypoallergenic recombinant fragments of the major birch pollen allergen, Bet v 1, induce blocking antibodies. J Immunol 2000, 165:6653-6659.
31. Ball T., Linhart B., Sonneck K., Blatt K., Herrmann H., Valent P., et al. Reducing allergenicity by altering allergen fold: a mosaic protein of Phl p 1 for allergy vaccination. Allergy 2009, 64:569-580.
32. Valenta R., Kraft D. Recombinant allergen molecules: tools to study effector cell activation. Immunol Rev 2001, 179:119-127.
33. Ball T., Vrtala S., Sperr W.R., Valent P., Susani M., Kraft D., et al. Isolation of an immunodominant IgE hapten from an epitope expression cDNA library. Dissection of the allergic effector reaction. J Biol Chem 1994, 269:28323-28328.
34. Zeiler T., Taivainen A., Rytkönen M., Rautiainen J., Karjalainen H., Mäntyjärvi R., et al. Recombinant allergen fragments as candidate preparations for allergen immunotherapy. J Allergy Clin Immunol 1997, 100:721-727.
35. Elfman L.H., Whitley P., Schmidt M., van Hage-Hamsten M. IgE binding capacity of synthetic and recombinant peptides of the major storage mite (Lepidoglyphus destructor) allergen, Lep d 2. Int Arch Allergy Immunol 1998, 117:167-173.
36. Mothes-Luksch N., Stumvoll S., Linhart B., Focke M., Krauth M.T., Hauswirth A., et al. Disruption of allergenic activity of the major grass pollen allergen Phl p 2 by reassembly as a mosaic protein. J Immunol 2008, 181:4864-4873.
37. Westritschnig K., Linhart B., Focke-Tejkl M., Pavkov T., Keller W., Ball T., et al. A hypoallergenic vaccine obtained by tail-to-head restructuring of timothy grass pollen profilin, Phl p 12, for the treatment of cross-sensitization to profilin. J Immunol 2007, 179:7624-7634.
38. Chen K.W., Fuchs G., Sonneck K., Gieras A., Swoboda I., Douladiris N., et al. Reduction of the in vivo allergenicity of Der p 2, the major house-dust mite allergen, by genetic engineering. Mol Immunol 2008, 45:2486-2498.
39. Campana R., Vrtala S., Maderegger B., Jertschin P., Stegfellner G., Swoboda I., et al. Hypoallergenic derivatives of the major birch pollen allergen Bet v 1 obtained by rational sequence reassembly. J Allergy Clin Immunol 2010, 126:1024-1031.
40. Linhart B., Mothes-Luksch N., Vrtala S., Kneidinger M., Valent P., Valenta R. A hypoallergenic hybrid molecule with increased immunogenicity consisting of derivatives of the major grass pollen allergens, Phl p 2 and Phl p 6. Biol Chem 2008, 389:925-933.
41. King T.P., Jim S.Y., Monsalve R.I., Kagey-Sobotka A., Lichtenstein L.M., Spangfort M.D. Recombinant allergens with reduced allergenicity but retaining immunogenicity of the natural allergens: hybrids of yellow jacket and paper wasp venom allergen antigen 5s. J Immunol 2001, 166:6057-6065.
42. Karamloo F., Schmid-Grendelmeier P., Kussebi F., Akdis M., Salagianni M., von Beust B.R., et al. Prevention of allergy by a recombinant multi-allergen vaccine with reduced IgE binding and preserved T cell epitopes. Eur J Immunol 2005, 35:3268-3276.
43. Linhart B., Valenta R. Vaccine engineering improved by hybrid technology. Int Arch Allergy Immunol 2004, 134:324-331.
44. Campana R., Vrtala S., Maderegger B., Dall'Antonia Y., Zafred D., Blatt K., et al. Altered IgE epitope presentation: a model for hypoallergenic activity revealed for Bet v 1 trimer. Mol Immunol 2011, 48:431-441.
45. van Hage-Hamsten M., Johansson E., Roquet A., Peterson C., Andersson M., Greiff L., et al. Nasal challenges with recombinant derivatives of the major birch pollen allergen Bet v 1 induce fewer symptoms and lower mediator release than rBet v 1 wild-type in patients with allergic rhinitis. Clin Exp Allergy 2002, 32:1448-1453.
46. van Hage-Hamsten M., Kronqvist M., Zetterström O., Johansson E., Niederberger V., Vrtala S., et al. Skin test evaluation of genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1: results obtained with a mix of two recombinant Bet v 1 fragments and recombinant Bet v 1 trimer in a Swedish population before the birch pollen season. J Allergy Clin Immunol 1999, 104:969-977.
47. Olsson S., van Hage-Hamsten M., Whitley P. Contribution of disulphide bonds to antigenicity of Lep d 2, the major allergen of the dust mite Lepidoglyphus destructor. Mol Immunol 1998, 35:1017-1023.
48. Ferreira F., Ebner C., Kramer B., Casari G., Briza P., Kungl A.J., et al. Modulation of IgE reactivity of allergens by site-directed mutagenesis: potential use of hypoallergenic variants for immunotherapy. FASEB J 1998, 12:231-242.
49. Okada T., Swoboda I., Bhalla P.L., Toriyama K., Singh M.B. Engineering of hypoallergenic mutants of the Brassica pollen allergen, Bra r 1, for immunotherapy. FEBS Lett 1998, 434:255-260.
50. Bannon G.A., Cockrell G., Connaughton C., West C.M., Helm R., Stanley J.S., et al. Engineering, characterization and in vitro efficacy of the major peanut allergens for use in immunotherapy. Int Arch Allergy Immunol 2001, 124:70-72.
51. Bonura A., Amoroso S., Locorotondo G., Di Felice G., Tinghino R., Geraci D., et al. Hypoallergenic variants of the Parietaria judaica major allergen Par j 1: a member of the non-specific lipid transfer protein plant family. Int Arch Allergy Immunol 2001, 126:32-40.
52. Swoboda I., De Weerd N., Bhalla P.L., Niederberger V., Sperr W.R., Valent P., et al. Mutants of the major ryegrass pollen allergen, Lol p 5, with reduced IgE-binding capacity: candidates for grass pollen-specific immunotherapy. Eur J Immunol 2002, 32:270-280.
53. Rabjohn P., West C.M., Connaughton C., Sampson H.A., Helm R.M., Burks A.W., et al. Modification of peanut allergen Ara h 3: effects on IgE binding and T cell stimulation. Int Arch Allergy Immunol 2002, 128:15-23.
54. Banerjee B., Kurup V.P., Greenberger P.A., Kelly K.J., Fink J.N. C-terminal cysteine residues determine the IgE binding of Aspergillus fumigatus allergen Asp f 2. J Immunol 2002, 169:5137-5144.
55. Westritschnig K., Focke M., Verdino P., Goessler W., Keller W., Twardosz A., et al. Generation of an allergy vaccine by disruption of the three-dimensional structure of the cross-reactive calcium-binding allergen, Phl p 7. J Immunol 2004, 172:5684-5692.
56. Buhot C., Chenal A., Sanson A., Pouvelle-Moratille S., Gelb M.H., Ménez A., et al. Alteration of the tertiary structure of the major bee venom allergen Api m 1 by multiple mutations is concomitant with low IgE reactivity. Protein Sci 2004, 13:2970-2978.
57. Drew A.C., Eusebius N.P., Kenins L., de Silva H.D., Suphioglu C., Rolland J.M., et al. Hypoallergenic variants of the major latex allergen Hev b 6.01 retaining human T lymphocyte reactivity. J Immunol 2004, 173:5872-5879.
58. Swoboda I., Bugajska-Schretter A., Linhart B., Verdino P., Keller W., Schulmeister U., et al. A recombinant hypoallergenic parvalbumin mutant for immunotherapy of IgE-mediated fish allergy. J Immunol 2007, 178:6290-6296.
59. González-Rioja R., Ibarrola I., Arilla M.C., Ferrer A., Mir A., Andreu C., et al. Genetically engineered hybrid proteins from Parietaria judaica pollen for allergen-specific immunotherapy. J Allergy Clin Immunol 2007, 120:602-609.
60. Vrtala S., Focke M., Kopec J., Verdino P., Hartl A., Sperr W.R., et al. Genetic engineering of the major timothy grass pollen allergen, Phl p 6, to reduce allergenic activity and preserve immunogenicity. J Immunol 2007, 179:1730-1739.
61. Marazuela E.G., Rodríguez R., Barber D., Villalba M., Batanero E. Hypoallergenic mutants of Ole e 1, the major olive pollen allergen, as candidates for allergy vaccines. Clin Exp Allergy 2007, 37:251-260.
62. Asturias J.A., Ibarrola I., Arilla M.C., Vidal C., Ferrer A., Gamboa P.M., et al. Engineering of major house dust mite allergens Der p 1 and Der p 2 for allergen-specific immunotherapy. Clin Exp Allergy 2009, 39:1088-1098.
63. Wald M., Kahlert H., Weber B., Jankovic M., Keller W., Cromwell O., et al. Generation of a low immunoglobulin E-binding mutant of the timothy grass pollen major allergen Phl p 5a. Clin Exp Allergy 2007, 37:441-450.
64. Valenta R., Hayek B., Seiberler S., Bugajska-Schretter A., Niederberger V., Twardosz A., et al. Calcium-binding allergens: from plants to man. Int Arch Allergy Immunol 1998, 117:160-166.
65. Kahlert H., Suck R., Weber B., Nandy A., Wald M., Keller W., et al. Characterization of a hypoallergenic recombinant Bet v 1 variant as a candidate for allergen-specific immunotherapy. Int Arch Allergy Immunol 2008, 145:193-206.
66. Toda M., Reese G., Gadermaier G., Schulten V., Lauer I., Egger M., et al. Protein unfolding strongly modulates the allergenicity and immunogenicity of Pru p 3, the major peach allergen. J Allergy Clin Immunol 2011, 128:1022-1030.
67. Beezhold D.H., Hickey V.L., Sussman G.L. Mutational analysis of the IgE epitopes in the latex allergen Hev b 5. J Allergy Clin Immunol 2001, 107:1069-1076.
68. Holm J., Gajhede M., Ferreras M., Henriksen A., Ipsen H., Larsen J.N., et al. Allergy vaccine engineering: epitope modulation of recombinant Bet v 1 reduces IgE binding but retains protein folding pattern for induction of protective blocking-antibody responses. J Immunol 2004, 173:5258-5267.
69. Greene W.K., Cyster J.G., Chua K.Y., O'Brien R.M., Thomas W.R. IgE and IgG binding of peptides expressed from fragments of cDNA encoding the major house dust mite allergen Der p I. J Immunol 1991, 147:3768-3773.
70. Padavattan S., Flicker S., Schirmer T., Madritsch C., Randow S., Reese G., et al. High-affinity IgE recognition of a conformational epitope of the major respiratory allergen Phl p 2 as revealed by X-ray crystallography. J Immunol 2009, 182:2141-2151.
71. Gieras A., Cejka P., Blatt K., Focke-Tejkl M., Linhart B., Flicker S., et al. Mapping of conformational IgE epitopes with peptide-specific monoclonal antibodies reveals simultaneous binding of different IgE antibodies to a surface patch on the major birch pollen allergen, Bet v 1. J Immunol 2011, 186:5333-5344.
72. Verdino P., Keller W. Circular dichroism analysis of allergens. Methods 2004, 32:241-248.
73. Westritschnig K., Horak F., Swoboda I., Balic N., Spitzauer S., Kundi M., et al. Different allergenic activity of grass pollen allergens revealed by skin testing. Eur J Clin Invest 2008, 38:260-267.
74. Lichtenstein L.M., Osler A.G. Studies in the mechanisms of hypersensitivity phenomena. IX. Histamine release from human leukocytes by ragweed pollen antigen. J Exp Med 1964, 120:507-530.
75. Hauswirth A.W., Natter S., Ghannadan M., Majlesi Y., Schernthaner G.H., Sperr W.R., et al. Recombinant allergens promote expression of CD203c on basophils in sensitized individuals. J Allergy Clin Immunol 2002, 110:102-109.
76. Pauli G., Purohit A., Oster J.P., De Blay F., Vrtala S., Niederberger V., et al. Comparison of genetically engineered hypoallergenic rBet v 1 derivatives with rBet v 1 wild-type by skin prick and intradermal testing: results obtained in a French population. Clin Exp Allergy 2000, 30:1076-1084.
77. Niederberger V., Stübner P., Spitzauer S., Kraft D., Valenta R., Ehrenberger K., et al. Skin test results but not serology reflects immediate type respiratory sensitivity: a study performed with recombinant allergen molecules. J Invest Dermatol 2001, 117:848-851.
78. Larché M., Akdis C.A., Valenta R. Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol 2006, 6:761-771.
79. O'Hehir R.E., Verhoef A., Panagiotopoulou E., Keswani S., Hayball J.D., Thomas W.R., et al. Analysis of human T cell responses to the group II allergen of Dermatophagoides species: localization of major antigenic sites. J Allergy Clin Immunol 1993, 92:105-113.
80. Ebner C., Szépfalusi Z., Ferreira F., Jilek A., Valenta R., Parronchi P., et al. Identification of multiple T cell epitopes on Bet v I, the major birch pollen allergen, using specific T cell clones and overlapping peptides. J Immunol 1993, 150:1047-1054.
81. Jahn-Schmid B., Kelemen P., Himly M., Bohle B., Fischer G., Ferreira F., et al. The T cell response to Art v 1, the major mugwort pollen allergen, is dominated by one epitope. J Immunol 2002, 169:6005-6011.
82. Purohit A., Niederberger V., Kronqvist M., Horak F., Grönneberg R., Suck R., et al. Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives. Clin Exp Allergy 2008, 38:1514-1525.
83. Campana R., Mothes N., Rauter I., Vrtala S., Reininger R., Focke-Tejkl M., et al. Non-IgE-mediated chronic allergic skin inflammation revealed with rBet v 1 fragments. J Allergy Clin Immunol 2008, 121:528-530.
84. Focke M., Swoboda I., Marth K., Valenta R. Developments in allergen-specific immunotherapy: from allergen extracts to allergy vaccines bypassing allergen-specific immunoglobulin E and T cell reactivity. Clin Exp Allergy 2010, 40:385-397.
85. Vrtala S., Ball T., Spitzauer S., Pandjaitan B., Suphioglu C., Knox B., et al. Immunization with purified natural and recombinant allergens induces mouse IgG1 antibodies that recognize similar epitopes as human IgE and inhibit the human IgE-allergen interaction and allergen-induced basophil degranulation. J Immunol 1998, 160:6137-6144.
86. Epstein M.M. Do mouse models of allergic asthma mimic clinical disease?. Int Arch Allergy Immunol. 2004, 133:84-100.
87. Seitzer U., Bussler H., Kullmann B., Petersen A., Becker W.M., Ahmed J. Characterization of immunoglobulin E responses in Balb/c mice against the major allergens of timothy grass (Phleum pratense) pollen. Clin Exp Allergy 2003, 33:669-675.
88. Mahler V., Vrtala S., Kuss O., Diepgen T.L., Suck R., Cromwell O., et al. Vaccines for birch pollen allergy based on genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1. Clin Exp Allergy 2004, 34:115-122.
89. Finkelman F.D., Wills-Karp M. Usefulness and optimization of mouse models of allergic airway disease. J Allergy Clin Immunol 2008, 121:603-606.
90. Klimek L., Bachert C., Doemer C., Meyer H., Narkus A. Specific immunotherapy with recombinant birch pollen allergen rBet v 1-FV is clinically efficacious. Allergy Clin Immunol Int 2005, 2005(Suppl. 1):15.
91. Rak S. Clinical results with a hypoallergenic recombinant birch pollen allergen derivative. Presented at 27th Congress, EAACI 2009 2009.
92. Valenta R., Linhart B., Swoboda I., Niederberger V. Recombinant allergens for allergen-specific immunotherapy: 10 years anniversary of immunotherapy with recombinant allergens. Allergy 2011, 66:775-783.
93. Valenta R., Niespodziana K., Focke-Tejkl M., Marth K., Huber H., Neubauer A., et al. Recombinant allergens: what does the future hold?. J Allergy Clin Immunol 2011, 127:860-864.
94. Niederberger V., Reisinger J., Valent P., Krauth M.T., Pauli G., van Hage M., et al. Vaccination with genetically modified birch pollen allergens: immune and clinical effects on oral allergy syndrome. J Allergy Clin Immunol 2007, 119:1013-1016.
95. Reisinger J., Horak F., Pauli G., van Hage M., Cromwell O., König F., et al. Allergen-specific nasal IgG antibodies induced by vaccination with genetically modified allergens are associated with reduced nasal allergen sensitivity. J Allergy Clin Immunol 2005, 116:347-354.
96. Gafvelin G., Thunberg S., Kronqvist M., Grönlund H., Grönneberg R., Troye-Blomberg M., et al. Cytokine and antibody responses in birch-pollen-allergic patients treated with genetically modified derivatives of the major birch pollen allergen Bet v 1. Int Arch Allergy Immunol 2005, 138:59-66.
97. Pree I., Reisinger J., Focke M., Vrtala S., Pauli G., van Hage M., et al. Analysis of epitope-specific immune responses induced by vaccination with structurally folded and unfolded recombinant Bet v 1 allergen derivatives in man. J Immunol 2007, 179:5309-5316.
98. Loveless M.H. Immunological studies on pollinosis. I. The presence of two antibodies related to the same pollen antigen in the serum of treated hay-fever patients. J Immunol 1940, 38:25-50.
99. Jung C.M., Prinz J.C., Rieber E.P., Ring J. A reduction in allergen-induced Fc epsilon R2/CD23 expression on peripheral B cells correlates with successful hyposensitization in grass pollinosis. J Allergy Clin Immunol 1995, 95:77-87.
100. van der Heijden F.L., Joost van Neerven R.J., van Katwijk M., Bos J.D., Kapsenberg M.L. Serum-IgE-facilitated allergen presentation in atopic disease. J Immunol 1993, 150:3643-3650.
101. van Neerven R.J., Wikborg T., Lund G., Jacobsen B., Brinch-Nielsen A., Arnved J., et al. Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4+ T cells by inhibiting serum-IgE-facilitated allergen presentation. J Immunol 1999, 163:2944-2952.
102. van Neerven R.J., Knol E.F., Ejrnaes A., Würtzen P.A. IgE-mediated allergen presentation and blocking antibodies: regulation of T-cell activation in allergy. Int Arch Allergy Immunol 2006, 141:119-129.
103. van Neerven R.J., Arvidsson M., Ipsen H., Sparholt S.H., Rak S., Würtzen P.A. A double-blind, placebo-controlled birch allergy vaccination study: inhibition of CD23-mediated serum-immunoglobulin E-facilitated allergen presentation. Clin Exp Allergy 2004, 34:420-428.
104. Würtzen P.A., Lund G., Lund K., Arvidsson M., Rak S., Ipsen H. A double-blind placebo-controlled birch allergy vaccination study II: correlation between inhibition of IgE binding, histamine release and facilitated allergen presentation. Clin Exp Allergy 2008, 38:1290-1301.
105. Pree I., Shamji M.H., Kimber I., Valenta R., Durham S.R., Niederberger V. Inhibition of CD23-dependent facilitated allergen binding to B cells following vaccination with genetically modified hypoallergenic Bet v 1 molecules. Clin Exp Allergy 2010, 40:1346-1352.
106. Shamji M.H., Wilcock L.K., Wachholz P.A., Dearman R.J., Kimber I., Wurtzen P.A., et al. The IgE-facilitated allergen binding (FAB) assay: validation of a novel flow-cytometric based method for the detection of inhibitory antibody responses. J Immunol Methods 2006, 317:71-79.
107. Naclerio R.M., Adkinson N.F., Moylan B., Baroody F.M., Proud D., Kagey-Sobotka A., et al. Nasal provocation with allergen induces a secondary serum IgE antibody response. J Allergy Clin Immunol 1997, 100:505-510.
108. Niederberger V., Ring J., Rakoski J., Jager S., Spitzauer S., Valent P., et al. Antigens drive memory IgE responses in human allergy via the nasal mucosa. Int Arch Allergy Immunol 2007, 142:133-144.
109. Mothes N., Heinzkill M., Drachenberg K.J., Sperr W.R., Krauth M.T., Majlesi Y., et al. Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin Exp Allergy 2003, 33:1198-1208.
110. Creticos P.S., Schroeder J.T., Hamilton R.G., Balcer-Whaley S.L., Khattignavong A.P., Lindblad R., et al. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 2006, 355:1445-1455.
111. Focke M., Mahler V., Ball T., Sperr W.R., Majlesi Y., Valent P., et al. Nonanaphylactic synthetic peptides derived from B cell epitopes of the major grass pollen allergen, Phl p 1, for allergy vaccination. FASEB J 2001, 15:2042-2044.
112. Focke M., Linhart B., Hartl A., Wiedermann U., Sperr W.R., Valent P., et al. Non-anaphylactic surface-exposed peptides of the major birch pollen allergen, Bet v 1, for preventive vaccination. Clin Exp Allergy 2004, 34:1525-1533.
113. Edlmayr J., Niespodziana K., Linhart B., Focke-Tejkl M., Westritschnig K., Scheiblhofer S., et al. A combination vaccine for allergy and rhinovirus infections based on rhinovirus-derived surface protein VP1 and a nonallergenic peptide of the major timothy grass pollen allergen Phl p 1. J Immunol 2009, 182:6298-6306.
114. Niespodziana K., Focke-Tejkl M., Linhart B., Civaj V., Blatt K., Valent P., et al. A hypoallergenic cat vaccine based on Fel d 1-derived peptides fused to hepatitis B PreS. J Allergy Clin Immunol 2011, 127:1562-1570.
115. Twaroch T.E., Focke M., Civaj V., Weber M., Balic N., Mari A., et al. Carrier-bound, nonallergenic Ole e 1 peptides for vaccination against olive pollen allergy. J Allergy Clin Immunol 2011, 128:178-184.